FDA Contributes Funds To Industry Post-Stenting Antiplatelet Trial
This article was originally published in The Gray Sheet
Executive Summary
FDA is contributing $1.5 million to a large, collaborative clinical study designed to find out the optimum length of time to give anti-clotting drugs to patients with coronary drug-eluting stents
You may also be interested in...
Longer Anti-Platelet Therapy Reduces Thrombosis Risks With Drug-Eluting Stents
In patients implanted with drug-eluting stents, dual antiplatelet drug therapy beyond one year significantly reduces the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events compared to aspirin alone, but also increase the risk of bleeding, the Dual Antiplatelet Therapy Trial show.
Researchers Urge More Company-To-Company Collaboration On Clinical Trials
With cost and time commitments ballooning for device and drug clinical development, some prominent researchers are pressing for companies with similar products to join together on new FDA pivotal trials rather than go it alone.
Researchers Urge More Company-To-Company Collaboration On Clinical Trials
With cost and time commitments ballooning for device and drug clinical development, some prominent researchers are pressing for companies with similar products to join together on new FDA pivotal trials rather than go it alone.